Education
About Us
Working with TipRanks
Follow Us
Catalyst Pharmaceutical Partners (CPRX)
:CPRX
Earnings Data
Report Date
Nov 05, 2025After Close (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
0.33Last Year’s EPS
0.35Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance with significant revenue growth across key products, particularly FIRDAPSE and AGAMREE. However, challenges remain with the decline in FYCOMPA revenue due to generic competition and increased operational expenses. The strategic initiatives and strengthened leadership team position Catalyst for sustained growth, though uncertainties in patent litigation may impact future performance.Company Guidance
Record-Setting Revenue Growth
Catalyst Pharmaceuticals reported total revenue of $146.6 million for Q2 2025, a 19.4% year-over-year increase. The first half of 2025 saw a 30.2% increase in total revenue, reaching $288 million.
Strong Performance of FIRDAPSE
FIRDAPSE generated net product revenue of $84.8 million in Q2 2025, a $7.5 million increase compared to Q2 2024. The first half of 2025 saw a 16.9% increase in net product revenue over the same period in 2024.
AGAMREE's Exceptional Growth
AGAMREE achieved $27.4 million in Q2 2025 net product revenue, a 213% increase year-over-year. The first half of 2025 saw a 398% increase in net revenues.
Strong Cash Position
The company ended Q2 2025 with a cash position of $652.8 million, showcasing its ability to invest strategically for long-term growth.
New Leadership and Strategic Initiatives
Dr. Will Andrews joined as Chief Medical Officer, and Dr. Dan Curran was added to the Board of Directors, strengthening the leadership team.
CPRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CPRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 06, 2025 | $21.79 | $19.64 | -9.87% |
May 07, 2025 | $23.46 | $22.76 | -2.98% |
Feb 26, 2025 | $20.58 | $21.66 | +5.25% |
Nov 06, 2024 | $22.71 | $23.25 | +2.38% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Catalyst Pharmaceutical Partners (CPRX) report earnings?
Catalyst Pharmaceutical Partners (CPRX) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).
What is Catalyst Pharmaceutical Partners (CPRX) earnings time?
Catalyst Pharmaceutical Partners (CPRX) earnings time is at Nov 05, 2025, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CPRX EPS forecast?
CPRX EPS forecast for the fiscal quarter 2025 (Q3) is 0.33.